Cybin (HELP) Cost of Revenue (2020 - 2022)

Cybin (HELP) reported Cost of Revenue of $274108.8 for Q2 2022, down 42.76% quarter-over-quarter from $478879.4 in Q2 2020.

Cybin (HELP) Cost of Revenue (2020 - 2022) Analysis & Trends

Cybin has reported Cost of Revenue for 2 years, with the latest figure at $274108.8 in Q2 2022.

For the quarter ending Q2 2022, Cost of Revenue changed N/A year-over-year to $274108.8; the trailing twelve-month figure through May 2022 stood at $274108.8 (changed N/A YoY), and the FY2023 full-year result was $1.7 million, changed N/A from the prior year.
Cost of Revenue for Q2 2022 stood at $274108.8, down from $478879.4 in the prior quarter.
The five-year high for Cost of Revenue was $478879.4 in Q2 2020, with the low at $274108.8 in Q2 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Cost of Rev (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	64.20 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	48,670.00
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	392.80 Mn
9	Abivax	91.96 Bn	91.96 Bn	-	2.05 Mn
10	Cybin	75.42 Mn	75.42 Mn	-	-

Download Data